Search

888 443 3311
    Clarient facebook  Clarient Twitter

EGFR Mutation Analysis


Methodology

Molecular/PCR

Specimen Requirements

  • Formalin-fixed, paraffin-embedded tissue or unstained slides – preferred.
  • Fresh snap frozen biopsy or FNA materials.

CPT Codes

  • 83907, 83900(x2), 83901(x18), 83891, 83896(x29), 83898(x6), 88381, 83914(x29), 83912-26

Highlights

  • Real-time PCR assay to detect the most common mutations of the EGFR gene.
  • Patients with EGFR mutations respond more favorably to EGFR tyrosine kinase inhibitors than those who don’t harbor a mutation.
     

Clinical Significance

The Epidermal Growth Factor Receptor (EGFR) activates an important pathway that leads to cell proliferation, differentiation, migration/motility, adhesion, protection from apoptosis, enhanced survival and gene transcription. A large body of experimental and clinical work supports the view that EGFR is a relevant target for cancer therapy. The development of selective tyrosine kinase inhibitors has become an important area of drug discovery for the treatment of a variety of solid tumors such as breast, ovarian and colorectal cancers, NSCLC, and carcinoma of the head and neck.

EGFR mutations can be seen in about 10-15% of patients. Patients with EGFR mutations have been reported to respond to selective anti-EGFR tyrosine kinase inhibitors. The EGFR mutation test offered by Clarient will be able to detect these mutations and identify all those patients that may respond to these targeted therapies.

 

Turnaround Time

5-7 days

References

  1. Cappuzzo F, Finocchiaro G, Metro G, et al. Clinical experience with gefitinib: an update. Crit Rev Oncol Hematol 2006;58:31-45.

  2. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004;304:1497-500.

  3. Sequist LV, Joshi VA, Janne PA, et al. Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing. Oncologist 2007;12:90-8.

  4. Ji H, Li D, Chen L, et al. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.Cancer Cell 2006;9:485-95.

If you would like your local Clarient representative to provide more information or to assist in any way, please register today!



Molecular Marker EGFR Pathway 

 


 

 

 

 

Print